Product Description
Autologous CD8+ and CD4+ T-cells transduced with TCR A2-MCC1
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fred Hutchinson Cancer Research Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Renal Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IMU-H20-30-P1 | P1 |
Completed |
Renal Cell Carcinoma |
2010-12-01 |